Biology of T Cells: Part A, Volume 341, the latest release in the International Review of Cell and Molecular Biology, reviews and details current advances in cell and molecular biology. The IRCMB series maintains the highest standard by publishing timely topics authored by prominent cell and molecular biologists. Specialized topics in this release include TCR signaling: Molecules and mechanisms, TCR diversity: Purpose and generation, Transcriptional programs underlying T-cell differentiation and function, Surface phenotypes of CD8+ and CD4+ T cells, Co-stimulation and co-inhibition in CD8+ and CD4+ T cells, Regulated cell death and T cells, Molecular mechanisms behind T-cell priming by DCs, and more.
Biology of T Cells - Part A jetzt bestellen!
Zielgruppe
<p>Undergraduate and graduate students and experienced researchers working and studying in all fields of cell and molecular biology</p>
Weitere Infos & Material
1. TCR signaling: Molecules and mechanisms 2. TCR diversity: Purpose and generation 3. Transcriptional programs underlying T-cell differentiation and function 4. Surface phenotypes of CD8+ and CD4+ T cells 5. Co-stimulation and co-inhibition in CD8+ and CD4+ T cells 6. Regulated cell death and T cells 7. Molecular mechanisms behind T-cell priming by DCs 8. Effect of macrophages on T cells
Rudqvist, Nils-Petter
Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-Petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.
